InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.16
(
0.47%
)
US TECH 100
18,024.00
(
0.56%
)
Dow Jones
39,497.54
(
0.13%
)
Brent Oil
79.49
(
0.00%
)
Bitcoin
60,680.33
(
-0.33%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120250
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 4404

Sunday, 08/05/2007 3:41:31 PM

Sunday, August 05, 2007 3:41:31 PM

Post# of 19309
In the interests of equal time… Artisan Pharma’s phase-2 trial in DIC/sepsis, which has been discussed on this board from time to time, is now open for enrollment at five US sites. (‘Rajuramas’ noted this trial’s listing on clinicaltrials.gov in June, but the trial was not yet open for enrollment at that time.)

http://www.clinicaltrials.gov/ct/show/NCT00487656

ART-123, the product candidate Artisan is developing for DIC, is not antithrombin; rather, it is thrombomodulin, a different molecule in the anticoagulation cascade that increases the inhibitory effect of antithrombin on thrombin.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up